Last updated on March 2019

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of LY2951742 in Patients with Episodic Migraine


Brief description of study

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of LY2951742 in Patients with Episodic Migraine

Detailed Study Description

To assess the efficacy and safety of two doses of LY2951742 in the prevention of migraine headache compared with placebo in patients suffering from episodic migraine. Episodic migraine is defined as 4-14 migraine headache days (with or without aura) per month.

Clinical Study Identifier: TX143172

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.